Sat, Aug 30, 2014, 2:33 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm Jul 7, 2013 7:56 PM Flag

    Report : Combinations of various Vertex drugs could benefit 90% of cystic fibrosis patients.

    We can ignore the usual cast of clowns fuddorainkvncmjesse etc..... The market will be shared among a few (3-8) inferiority drugs in the TOBI market segment of aprx 400 million. The full CF market of course is much larger. I see the confusion among the mutually masturbating idiots that now the trading community has showed how ignorant they are( shorts will get crushed!! ,....they come up with a different blcht story.
    Read the Wedbush which is heavily slanted ( so much for those valued analysts ) who has dedicated a possible size of 75 M . Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • We can ignore the usual cast of clowns fuddorainkvncmjesse etc..... The market will be shared among a few (3-8) inferiority drugs in the TOBI market segment of aprx 400 million. The full CF market of course is much larger. I see the confusion among the mutually masturbating idiots that now the trading community has showed how ignorant they are( shorts will get crushed!! ,....they come up with a different blcht story.
      Read the Wedbush which is heavily slanted ( so much for those valued analysts ) who has dedicated a possible size of 75 M

    • bump

    • Aradigm takes a deep breath with Grifols deal
      A global licensing deal last month with Spain’s Grifols (NASDAQ:GRFS), valued at up to $90-million plus royalties, gives Aradigm a well-heeled partner to complete pivotal testing of its inhaled formulations of ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis .
      Aradigm will take the lead on the development front, taking its Pulmaquin once-daily inhaled ciprofloxacin into global Phase 3 clinical trials for BE.
      In addition, he says Grifols and Aradigm can develop Pulmaquin, or other forms of inhaled ciprofloxacin, for other diseases.
      For example, Aradigm’s liposomal ciprofloxacin has been successfully tested in patients with cystic fibrosis and in animal models of several bioterrorism infections.

      • 2 Replies to backwardpalm
      • Aradigm needed a deal but they are not Insmeds competitor should Insmed succeed relatively quickly from their latest disaster. TIP, from pharma powerhouse Novartis has power that reaches beyond marketing.Start at the FDA where Novartis pays a good chunk to fund the agency

      • Aradigm takes a deep breath with Grifols deal
        A global licensing deal last month with Spain’s Grifols (NASDAQ:GRFS), valued at up to $90-million plus royalties, gives Aradigm a well-heeled partner to complete pivotal testing of its inhaled formulations of ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis .
        Aradigm will take the lead on the development front, taking its Pulmaquin once-daily inhaled ciprofloxacin into global Phase 3 clinical trials for BE.
        In addition, he says Grifols and Aradigm can develop Pulmaquin, or other forms of inhaled ciprofloxacin, for other diseases.
        For example, Aradigm’s liposomal ciprofloxacin has been successfully tested in patients with cystic fibrosis and in animal models of several bioterrorism infections.

 
INSM
13.93+0.11(+0.80%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.